Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
Completed · Phase 2 · NCT05262270
Conditions: Cocaine Use Disorder
At a glance
- Research payments reported, 2025
- $7,922
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 427
About the trial
- Sponsor
- University of Texas Southwestern Medical Center (with National Institute on Drug Abuse (NIDA))
- Tested
- Extended-Release Naltrexone (drug), Extended Release Buprenorphine (drug), Placebo (PLB) Injectable matched to XR-NTX (drug), Placebo (PLB) Injectable matched to XR-BUP (drug)
- Dates
- Started 2023-04-18; completion 2025-07-21
- Results posted
- Not yet
This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).
From ClinicalTrials.gov, last updated 2025-10-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Indivior Inc. reported $7,922 in research payments for this study in 2025 (2 payments).
Products named: Sublocade
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- National Institute on Drug Abuse $7,922
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.